Navigation Links
New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
Date:4/1/2009

death back to life," says PhRMA President and CEO Billy Tauzin. "The men and women working for America's pharmaceutical research companies are committed to developing new cancer medicines that, one day, could eradicate cancer all together."

Cancer medicines being developed include 122 for lung cancer, the leading cause of cancer death in the United States; 107 for breast cancer, which is expected to strike more than 180,000 American women this year; 70 for colorectal cancer, which is the third most common cancer in both men and women; and 103 for prostate cancer, which this year is expected to kill 28,000 American men. Additional medicines target brain cancer, kidney cancer, ovarian cancer, pancreatic cancer, skin cancer, and others.

The medicines represent many cutting-edge approaches, including a drug that delivers a synthetic version of a substance derived from scorpions directly to brain tumor cells; a number of cancer vaccines; medicines that target and kill specific cancer cells; and treatments that activate the patient's general immune system to destroy cancer.

"Researchers are making exciting progress in the search for new cures and treatments for cancer. But these efforts are wasted if the medicines we develop aren't accessible to patients who need them," said Johnson.

Help is available to patients in need through the Partnership for Prescription Assistance (PPA), a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped more than 5.7 million patients nationwide, including more than 72,000 people in Colorado. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,500 cities to educate people about patient assistance programs.

The "Help is Here Express" is staffed by trained specialists able to quickly help uninsured and financially struggling patients access information on more than 475 patient as
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
2. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
5. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
6. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
7. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
8. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
11. New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Harmony Foundation, Colorado,s ... Estes Park , will break ground for a new ... am on Harmony,s campus. The public is welcome to attend ... of Harmony,s $10 million Support & Renew Capital Campaign ... and complex addiction rates in Colorado . ...
(Date:7/14/2014)...  More than any other generation, Millennials born in the ... but their eyes don,t. These mobile devices demand a type ... eye has not evolved to cope with them. The gap ... comfortably often results in tired eyes, focusing problems, headaches and ... Now ZEISS has invented a new type of lens for ...
(Date:7/14/2014)...  GenSpera, Inc. (OTCQB: GNSZ), a leader in ... announces that Kareg Corporation,s Director of Research, ... research report on  the company. ... Kareg Corporation, Initiating Coverage with a Speculative Buy ... http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ is attractive ...
Breaking Medicine Technology:Harmony Foundation Breaking Ground on Addiction Health Center 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6
(Date:7/14/2014)... Academy, senescent is he who "begins to age". But ... is senescence not a synonym of ageing, it is ... is such a badly named physiological process that those ... another name. That is the case of Manuel Serrano, ... of the world,s leading experts on senescence, who has ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 The ... & Services [Physical Security, Life Safety, Facility Management], ... Worldwide Forecast & Analysis (2014 - 2019)” defines ... with an in-depth analysis and forecasting of revenues. ... market, various restraints and opportunities impacting it, along ...
(Date:7/14/2014)... into an agreement with one of the world,s ... candidates for the detection and treatment of cancer. ... antibody discovery and Roche,s expertise in developing monoclonal ... of improved treatment for cancer, a leading cause ... use of BTI,s discovery of a new mechanism ...
(Date:7/14/2014)... Secure Decisions, a leading provider of assessment ... Software Assurance Marketplace (SWAMP) to build a powerful and ... everyday life. , The SWAMP, implemented by a group ... Institute for Research, is funded by the Department of ... by building a free facility with a diverse repository ...
(Date:7/14/2014)... with improving vision, cataract surgery may slow mental decline ... dementia, a new study suggests. Better eyesight also ... "These preliminary results indicate that improved vision can have ... their loved ones, both visual and non-visual," said Dr. ... Hospitals Case Medical Center, in Ohio. Cataract surgery ...
Breaking Medicine News(10 mins):Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2
... , Preliminary research on Fusarium , a group ... animals, shows how these microbes travel through the air. ... preliminary research, there will be a better understanding about ... biologists are steering their efforts towards a new aerobiological ...
... malaria vaccine that uses the entire malaria parasite has proven ... in a clinical trial, according to a new study co-authored ... Center for Vaccine Development. The vaccine is unique in that ... vaccines consist of just one or at most a few ...
... Institute in Boston and the Scripps Research Institute in ... powerful anti-diabetic effects, yet apparently free at least ... current diabetes medications. The researchers say that their ... 2 diabetes, which affects more than 25 million children ...
... HealthDay Reporter , FRIDAY, Sept. 9 (HealthDay News) -- ... were to meet Friday to discuss problems linked to ... Boniva and Reclast. These drugs, known as ... osteoporosis. But researchers have linked long-term use with a ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- Many ... infant. But sometimes that concern develops into an obsession over ... that condition postpartum obsessive compulsive disorder. It can drive women ... true, such as endlessly washing the infant to stave off ...
... at the University of Ottawa Heart Institute (UOHI) have ... and exports cholesterol from cells. A team ... Biology Laboratory, UOHI, has shown that autophagy, a pathway ... accumulated in artery walls. This process facilitates the removal ...
Cached Medicine News:Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 2Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 3Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 4Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 5Health News:New twist in diabetes drugs could reduce life-threatening side effects 2Health News:New twist in diabetes drugs could reduce life-threatening side effects 3Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:When Protecting Baby Becomes an Obsession 2Health News:When Protecting Baby Becomes an Obsession 3Health News:Researchers find process that clears cholesterol and could reverse major cause of heart attack 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: